Partial upper sternotomy for aortic valve replacement provides similar mid-term outcomes as the full sternotomy.
Minimally invasive
aortic valve
partial sternotomy
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
11
09
2021
accepted:
26
02
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
ppublish
Résumé
Minimally invasive aortic valve replacement via upper partial sternotomy (MiniAVR) provides very good short-term results and delivers certain advantages in the postoperative course. There is limited data regarding the mid-term mortality and morbidity following this minimally invasive surgery. We provide a retrospective analysis of the patients, undergoing MiniAVR versus full sternotomy (FS) for aortic valve replacement with biological prosthesis. As the primary combined end-point the combination of death, stroke, and rehospitalization within 3 years postoperatively was defined. Data have been collected from National Cardiac Surgery Registry and insurance companies. Two hundred consecutive patients with aortic valve replacement (100 ministernotomy in MiniAVR group and 100 full sternotomy in FS group) with biological prosthesis were included in this study. Ministernotomy had longer cross-clamp and bypass times (median difference 6.5 min, P=0.005, and 8.5 min, P=0.002 respectively). Patients operated via upper partial sternotomy had a lower postoperative bleeding [300 mL (IQR, 290) Upper partial sternotomy can be performed safely for aortic valve replacement, without increased risk of death, stroke or re-admission in 3 years postoperatively.
Sections du résumé
Background
UNASSIGNED
Minimally invasive aortic valve replacement via upper partial sternotomy (MiniAVR) provides very good short-term results and delivers certain advantages in the postoperative course. There is limited data regarding the mid-term mortality and morbidity following this minimally invasive surgery.
Methods
UNASSIGNED
We provide a retrospective analysis of the patients, undergoing MiniAVR versus full sternotomy (FS) for aortic valve replacement with biological prosthesis. As the primary combined end-point the combination of death, stroke, and rehospitalization within 3 years postoperatively was defined. Data have been collected from National Cardiac Surgery Registry and insurance companies.
Results
UNASSIGNED
Two hundred consecutive patients with aortic valve replacement (100 ministernotomy in MiniAVR group and 100 full sternotomy in FS group) with biological prosthesis were included in this study. Ministernotomy had longer cross-clamp and bypass times (median difference 6.5 min, P=0.005, and 8.5 min, P=0.002 respectively). Patients operated via upper partial sternotomy had a lower postoperative bleeding [300 mL (IQR, 290)
Conclusions
UNASSIGNED
Upper partial sternotomy can be performed safely for aortic valve replacement, without increased risk of death, stroke or re-admission in 3 years postoperatively.
Identifiants
pubmed: 35572904
doi: 10.21037/jtd-21-1494
pii: jtd-14-04-857
pmc: PMC9096275
doi:
Types de publication
Journal Article
Langues
eng
Pagination
857-865Informations de copyright
2022 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-21-1494/coif). PT reports that he is supported by the scientific grant program of the Charles University Prague, Czech Republic (UNCE MED 02 and PROGRES Q38) and in the past received a part-time salary for lectures and presentations for the firms, Medtronic, B Braun and Abiomed. The other authors have no conflicts of interest to declare.
Références
Innovations (Phila). 2010 Jan;5(1):12-5
pubmed: 22437270
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Thorac Cardiovasc Surg. 2002 Dec;50(6):337-41
pubmed: 12457309
Eur J Cardiothorac Surg. 2018 May 1;53(suppl_2):ii3-ii8
pubmed: 29718230
Curr Probl Cardiol. 2006 Jun;31(6):399-437
pubmed: 16697902
Ann Thorac Surg. 2002 Oct;74(4):S1318-22
pubmed: 12400808
Ann Thorac Surg. 1999 Jun;67(6):1643-7
pubmed: 10391268
Tex Heart Inst J. 2017 Dec 19;44(6):390-394
pubmed: 29276437
Ann Thorac Surg. 2008 Mar;85(3):1121-31
pubmed: 18291224
Cochrane Database Syst Rev. 2017 Apr 10;4:CD011793
pubmed: 28394022
Ann Thorac Surg. 2014 Oct;98(4):1499-511
pubmed: 25064516
Ann Thorac Surg. 2013 Sep;96(3):837-43
pubmed: 23866805
Eur J Cardiothorac Surg. 2011 Sep;40(3):749-55
pubmed: 21342776
J Thorac Dis. 2013 Nov;5 Suppl 6:S662-8
pubmed: 24251025
Ann Thorac Surg. 1999 Dec;68(6):2209-13; discussion 2213-4
pubmed: 10617004
Eur J Cardiothorac Surg. 2013 Mar;43(3):580-4
pubmed: 22700588
Interact Cardiovasc Thorac Surg. 2018 Oct 1;27(4):481-486
pubmed: 29617839
J Thorac Cardiovasc Surg. 2008 Apr;135(4):732-8
pubmed: 18374749
Ann Thorac Surg. 1996 Aug;62(2):596-7
pubmed: 8694642
Ann Thorac Surg. 2015 Jan;99(1):17-25
pubmed: 25441065
J Thorac Dis. 2017 Jun;9(6):1672-1696
pubmed: 28740685
Ann Surg. 1997 Oct;226(4):421-6; discussion 427-8
pubmed: 9351710
J Thorac Cardiovasc Surg. 2014 Jan;147(1):6-14
pubmed: 24183904
J Thorac Cardiovasc Surg. 2009 Mar;137(3):670-679.e5
pubmed: 19258087
Medicina (Kaunas). 2018 Apr 28;54(2):
pubmed: 30344257
Ann Cardiothorac Surg. 2015 Jan;4(1):26-32
pubmed: 25694973